Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study (ARX517-2011, NCT04662580)
Year: 2023
Type: conference-abstract
Source: Cancer Research
Authors: John Shen, Richard Pachynski, Luke Nordquist, Nabil Adra, Mehmet Bilen, Rahul Aggarwal, Zachary Reichert, Michael Schweizer, Dong Xu, Manan Patel, Jin Zhang, Wenge Shi, Darryl Z. L'Heureux, Scott Tagawa
Institutions: University of California, Los Angeles, Washington University in St. Louis, Urology Cancer Center and GU Research Network, Indiana University School of Medicine, Emory University, University of California, San Francisco, University of Michigan, University of Washington, Ambrx (United States), Cornell University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4365513636